NCT02228590View on ClinicalTrials.gov

A Study to Examine APL-130277 in Patients With Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

November 24, 2014

Study Completion Date

November 24, 2014

Conditions
Parkinson's Disease
Interventions
DRUG

APL-130277

Apomorphine Hydrochloride, Sublingual Thin Film

Trial Locations (4)

33486

Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton

33613

University of South Florida Parkinson's Disease and Movement Disorders Center, Tampa

80113

Rocky Mountain Movement Disorders Center, Englewood

85351

Banner Sun Health Research Institute, Sun City

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT02228590 - A Study to Examine APL-130277 in Patients With Parkinson's Disease | Biotech Hunter | Biotech Hunter